Amy Proal | The Human Virome: a Driver of Aging
Biotech and Health Extension sponsored by 100 Plus Capital
The Human Virome: a Driver of Aging
Bio: Dr. Proal is a microbiologist and President/Chief Scientific Officer of PolyBio Research Foundation - a non-profit studying how viral, bacterial, and fungal infections contribute to chronic diseases and aging processes. She directs PolyBio's LongCovid Research Consortium: an international scientific collaboration to rapidly and openly study LongCovid, with a focus on the persistence of the SARS-CoV-2 virus in tissue. She also serves as Scientific Director of Mount Sinai's CoRE clinic, where she oversees the development of research studies and clinical trials aimed at controlling persistent infection, inflammaging, and metabolic dysfunction.
Abstract: This talk will explain how common viruses accumulated by humans over the course of a lifetime (the human virome) contribute to diseases of aging and inflammaging. These viruses, which include the herpesviruses, have evolved a wide range of mechanisms to directly hijack the activity of the human genome and human metabolism. They also modulate the immune response to drive aging processes. For example, the amyloid beta “plaque” that accumulates in the Alzheimer’s brain is now being studied as an immune peptide that forms in response to viral pathogens in brain tissue.
Indeed, proteins encoded by persistent viruses have been shown to distort human longevity signaling networks. For example, one analysis uncovered dozens of viruses encoding proteins experimentally demonstrated to interact with proteins from pathways associated with human aging, including cellular senescence. Viral infection can also have profound effects on host cell processes relevant to telomere biology and genome maintenance, with human herpesvirus 6 (HHV-6) capable of driving telomere dysfunction by directly integrating into host telomeric DNA.
Human virome-driven contributions to diseases of aging and general aging processes have been impacted by the COVID-19 pandemic. I lead the PolyBio LongCovid Research Consortium. We are increasingly studying the SARS-CoV-2 virus as capable of long-term persistence in a wide range of human body and brain sites. We may consequently be seeding the human population with yet one more virus that can drive human genome, metabolic, and senescence-related dysfunction under certain conditions.
However, the use of certain antiviral drugs, immunotherapies, or CRISPR-based approaches may control virome activity in a manner that should promote human longevity. I will discuss some of these therapeutic options and how they can be best incorporated into innovative anti-aging protocols and/or clinical trials.
Biotech and Health Extension sponsored by 100 Plus Capital
This seminar is part of Foresight's Longevity Biotech Group Seminar Series. To join future seminars in this program please apply here.
A group of scientists, entrepreneurs, funders, and institutional allies who cooperate to advance biotechnology to reverse aging and extend human healthspan. This group is sponsored by 100 Plus Capital.
Nominate a seminar presenter/topic
Feel free to reach out to lydia@foresight.org with any questions.